hs-CRP: The Inflammation Marker Your Doctor Probably Isn't Checking

C-reactive protein is a pattern recognition molecule — a member of the pentraxin family — produced primarily by hepatocytes in response to inflammatory cytokines, most importantly interleukin-6 (IL-6). In the acute phase response following tissue injury or infection, CRP rises rapidly (within 6–12 hours), can increase 1,000-fold or more above baseline, and declines within 72 hours of resolution.[1]

In the context of vascular inflammation, CRP is produced in response to the chronic low-grade inflammatory cytokine signal generated by developing atherosclerotic plaques, visceral adipose tissue macrophages, and metabolically active endothelium. This chronic vascular inflammatory signal operates in a range — typically 0.5–10 mg/L — that requires high-sensitivity measurement unavailable from standard assay platforms.

hs-CRP specifically uses nephelometric or turbidimetric assays with an analytical sensitivity of 0.1–0.3 mg/L, compared to standard CRP assays with sensitivities of 3–10 mg/L. This analytical distinction is what makes hs-CRP capable of detecting the vascular inflammatory signal that predicts cardiovascular events.

JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) enrolled 17,802 apparently healthy men and women with LDL <130 mg/dL and hs-CRP ≥2 mg/L — patients who would not have qualified for statin therapy under standard lipid guidelines but had evidence of chronic vascular inflammation. They were randomized to rosuvastatin 20 mg daily or placebo.[5]

The trial was stopped early by the Data Safety Monitoring Board because the benefit was so clear. The number needed to treat was comparable to statins in secondary prevention.

“JUPITER established that hs-CRP ≥2 mg/L identifies patients at elevated cardiovascular risk despite normal LDL — and that an inflammation-guided treatment strategy produces major event reduction in a population standard guidelines would not have treated.”

The 2018 ACC/AHA Cholesterol Management Guidelines formally incorporated hs-CRP ≥2 mg/L as a risk-enhancing factor that should inform shared decision making about statin initiation in intermediate-risk patients.[6]

Post-hoc analyses of multiple statin trials have demonstrated that patients with both elevated LDL and elevated hs-CRP derive the greatest absolute cardiovascular event reduction from statin therapy. Patients who achieve both LDL <70 mg/dL and hs-CRP <1.0 mg/L on statin therapy have significantly better outcomes than those who achieve only one target.[8]

This two-target framework — simultaneously targeting LDL and hs-CRP — provides a more complete treatment goal than LDL reduction alone and identifies patients whose inflammatory response to statin therapy is insufficient and may benefit from additional anti-inflammatory interventions such as low-dose colchicine or intensified lifestyle modification.

hs-CRP is not a novel or experimental biomarker. It has been validated in large prospective cohorts, incorporated into cardiovascular guidelines, and demonstrated as a therapeutic target in a landmark randomized controlled trial that changed clinical practice. The reason it is not routinely ordered at annual physicals is not scientific — it is structural, a consequence of a healthcare system that measures what reimbursement incentivizes rather than what risk assessment requires.

“The patient whose LDL is controlled but whose hs-CRP is chronically elevated is a patient whose vascular inflammatory risk remains inadequately characterized and managed. That patient deserves to know their number — and to work with a physician who knows what to do with it.”